Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
PR
Prelude Therapeutics Incorporated
PRLD
Mkt Cap
$259.0M
Volume
423.10K
Next Earnings
November 11th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
PR
PRLD
PR
Prelude Therapeutics Incorporated
PRLD
News
·
Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026
Mkt Cap
$260.2M
Volume
423.10K
Next Earnings
November 11th
Chart
Financials
Earnings
News
About
Insider
Filings
Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026
Prelude Therapeutics announced preclinical data for PRT13722, a first-in-class oral KAT6A degrader showing complete tumor regressions in HR+/HER2- breast cancer models with improved hematological safety compared to existing approaches. The company remains on track to file an IND application by mid-2026 and initiate clinical trials in the second half of 2026.
GlobeNewswire Inc. · Apr 20, 2026
Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs
Prelude Therapeutics presented preclinical data on two promising therapeutic approaches for myeloproliferative neoplasms (MPNs): a JAK2V617F-selective JH2 inhibitor (PRT12396) and a mutant calreticulin targeted degrader antibody conjugate, demonstrating potential disease-modifying capabilities.
GlobeNewswire Inc. · Dec 6, 2025
Prelude Cuts Q2 Losses and Costs 13%
Prelude Therapeutics reported a Q2 2025 net loss of $31.2 million, reduced operating expenses, and focused on its oral SMARCA2 degrader program while maintaining cash reserves to fund operations into Q2 2026.
The Motley Fool · Aug 14, 2025
Prelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial
Prelude Therapeutics announced positive initial clinical data for its SMARCA2 degrader PRT3789 in a Phase 1 trial, showing promising anti-tumor activity and a generally well-tolerated safety profile in patients with SMARCA4-mutated cancers.
GlobeNewswire Inc. · Sep 13, 2024
Prelude Therapeutics to Participate in Upcoming Healthcare Conferences
WILMINGTON, Del., June 03, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in two upcoming healthcare conferences in June.
GlobeNewswire Inc. · Jun 3, 2024
Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference
WILMINGTON, Del., May 09, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Citizens JMP Life Sciences Conference, taking place in New York City on May 13 and 14.
GlobeNewswire Inc. · May 9, 2024
Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
First-in-class IV SMARCA2 degrader, PRT3789 and potentially best-in-class CDK9 inhibitor, PRT2527 remain on track to generate initial proof-of-concept data in 2024
GlobeNewswire Inc. · May 7, 2024
Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting
Highly selective oral SMARCA2 degrader, PRT7732, shows robust anti-tumor activity in vivo as monotherapy and in combination with chemotherapy, at well-tolerated doses
GlobeNewswire Inc. · Apr 9, 2024
Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting
Prelude Therapeutics to present preclinical data posters at the 2024 AACR on its oral SMARCA2 degrader, CDK9 inhibitor and next-gen CDK4/6 inhibitor
GlobeNewswire Inc. · Mar 5, 2024
Prelude Therapeutics to Participate in Barclays Global Healthcare Conference
Prelude Therapeutics' Kris Vaddi and Jane Huang to participate in fireside chat at Barclay's Global Healthcare conference 2024 on March 13 in Miami
GlobeNewswire Inc. · Feb 29, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
PR
PRLD
Prelude Therapeutics Incorporated
Buy
Sell
Market
Limit
Soon
PRLD
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any PRLD yet.
Related Tickers
Earnings